Navigation Links
Sensipar® Patents Upheld By District Court
Date:1/7/2011

THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire/ -- A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.  The latest Sensipar expiry is in 2018.  Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

"We are pleased with the Court's ruling, which validates Amgen's position that the Sensipar patents are valid, enforceable and infringed," said David Scott, Amgen's senior vice president, general counsel and secretary. Scott added: "Amgen will continue to vigorously defend its innovative products from infringement."

Three patents were the subject of the injunction: U.S. Patent No. 6,011,068 ("the `068 patent") and U.S. Patent No. 6,031,003 expire Dec.14, 2016, but the `068 patent is the subject of a patent term extension which will extend the term to March 8, 2018.  U.S. Patent No. 6,211,244 expires Oct. 23, 2015.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.CONTACT: Amgen, Thousand OaksDavid Polk, 805-447-4613 (media)Arvind Sood, 805-447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
2. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
3. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
4. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
5. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
8. PDL BioPharma Receives Letter from Genentech Relating to European Patents
9. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
10. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
11. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
(Date:4/27/2016)... DELHI , April 27, 2016 ... CSR initiative to save newborns   ... hospital for women & newborns in collaboration with Breast Milk ... launched the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR ... best nutritional food source for infants and should be available ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today ... this week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, ... Europa Orlando Expo coming up April 29-30, was selected as the perfect event to ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households across ... from USA Medical Prescription Assistance Program. They are customized to reflect the specific ... will include a ready-to-use, state-themed card and, in the near future, material that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... ... April 28, 2016 , ... North Hollywood dentist , Dr. Hamid Reza, ... essential when it comes to dental accidents or critical dental problems. These issues can ... a tooth. Toothaches, knocked-out teeth, chipped teeth, and many other issues can lead to ...
(Date:4/28/2016)... OH (PRWEB) , ... April ... ... extending an invitation to those affected by a health insurance co-operative bankruptcy ... Hope’s proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from ...
Breaking Medicine News(10 mins):